Kasaija Paul D, Contreras Marinela, Kirunda Halid, Nanteza Ann, Kabi Fredrick, Mugerwa Swidiq, de la Fuente José
SaBio, Instituto de Investigación en Recursos Cinegéticos (IREC), Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Castilla-La Mancha (UCLM)-Junta de Comunidades de Castilla-La Mancha (JCCM), Ronda de Toledo s/n, 13005 Ciudad Real, Spain.
National Livestock Resources Research Institute (NaLIRRI), Kampala P.O. Box 5704, Uganda.
Vaccines (Basel). 2022 Dec 31;11(1):99. doi: 10.3390/vaccines11010099.
Ticks are worldwide ectoparasites to humans and animals, and are associated with numerous health and economic effects. Threatening over 80% of the global cattle population, tick and tick-borne diseases (TTBDs) particularly constrain livestock production in the East, Central and Southern Africa. This, therefore, makes their control critical to the sustainability of the animal industry in the region. Since ticks are developing resistance against acaricides, anti-tick vaccines (ATVs) have been proposed as an environmentally friendly control alternative. Whereas they have been used in Latin America and Australia to reduce tick populations, pathogenic infections and number of acaricide treatments, commercially registered ATVs have not been adopted in tropical Africa for tick control. This is majorly due to their limited protection against economically important tick species of Africa and lack of research. Recent advances in various omics technologies and reverse vaccinology have enabled the identification of many candidate anti-tick antigens (ATAs), and are likely to usher in the next generation of vaccines, for which Africa should prepare to embrace. Herein, we highlight some scientific principles and approaches that have been used to identify ATAs, outline characteristics of a desirable ATA for vaccine design and propose the need for African governments to investment in ATV research to develop vaccines relevant to local tick species (personalized vaccines). We have also discussed the prospect of incorporating anti-tick vaccines into the integrated TTBDs control strategies in the sub-Saharan Africa, citing the case of Uganda.
蜱虫是遍布全球的人类和动物体外寄生虫,会带来众多健康和经济影响。蜱虫及蜱传疾病(TTBDs)威胁着全球80%以上的牛群,尤其制约了东非、中非和南非的畜牧业生产。因此,对蜱虫的控制对于该地区畜牧业的可持续发展至关重要。由于蜱虫对杀螨剂产生了抗药性,抗蜱疫苗(ATVs)已被提议作为一种环境友好型的控制替代方案。尽管抗蜱疫苗已在拉丁美洲和澳大利亚用于减少蜱虫数量、致病性感染和杀螨剂处理次数,但在热带非洲尚未采用商业注册的抗蜱疫苗来控制蜱虫。这主要是因为它们对非洲具有经济重要性的蜱虫种类的保护有限,且缺乏相关研究。各种组学技术和反向疫苗学的最新进展已使许多候选抗蜱抗原(ATAs)得以鉴定,这可能会带来下一代疫苗,非洲应为此做好准备。在此,我们强调了一些用于鉴定抗蜱抗原的科学原理和方法,概述了疫苗设计中理想抗蜱抗原的特征,并提出非洲各国政府需要投资于抗蜱疫苗研究,以开发针对当地蜱虫种类的疫苗(个性化疫苗)。我们还以乌干达为例,讨论了将抗蜱疫苗纳入撒哈拉以南非洲蜱传疾病综合控制策略的前景。